Geneva, Switzerland, 11 September 2017 – 07:30 CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases, announced today that data supporting the role of pathogenic pHERV-W env in Type 1 diabetes has been published in The Journal of Clinical Investigation Insight. Pathogenic pHERV-W env is encoded by a member of the HERV-W family. HERVs are ancestral retroviral DNA insertions in the human genome, thought to account for up to 8% of the human genome.

More information on :